Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis
This systematic review and meta-analysis were conducted to evaluate the cardiac and kidney-related adverse effects of roxadustat for the treatment of anemia in CKD patients. 18 trials with a total of 8806 participants were identified for analysis. We employed a fixed-effects model for analysis. The...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2313864 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591096856707072 |
|---|---|
| author | Lei Tian Mengdi Wang Mengchao Liu Yanyu Pang Jingwen Zhao Bingjie Zheng Yutong Wang Wenjing Zhao |
| author_facet | Lei Tian Mengdi Wang Mengchao Liu Yanyu Pang Jingwen Zhao Bingjie Zheng Yutong Wang Wenjing Zhao |
| author_sort | Lei Tian |
| collection | DOAJ |
| description | This systematic review and meta-analysis were conducted to evaluate the cardiac and kidney-related adverse effects of roxadustat for the treatment of anemia in CKD patients. 18 trials with a total of 8806 participants were identified for analysis. We employed a fixed-effects model for analysis. The pooled result revealed no significant difference in the risk of occurrence of cardiac disorders when comparing CKD patients receiving roxadustat with the placebo (RR = 1.049; CI [0.918 to 1.200]) or ESA (RR = 1.066; CI [0.919 to 1.235]), in both dialysis-dependent (DD) (RR = 1.094; CI [0.925 to 1.293]) or non-dialysis-dependent (NDD) (RR = 1.036; CI [0.916 to 1.171]) CKD patients. No significant difference was observed in the risk of kidney-related adverse events when comparing roxadustat with the placebo (RR = 1.088; CI [0.980 to 1.209]) or ESA (RR = 0.968; CI [0.831 to 1.152]), in DD (RR = 2.649; CI [0.201 to 34.981]) or NDD (RR = 1.053; CI [0.965 to 1.149]) CKD patients. A high risk of hyperkalemia was observed in the roxadustat group in DD (RR = 0.939; CI [0.898 to 0.981]). Incidence of hypertension was higher in the roxadustat for NDD patients (RR = 1.198; CI [1.042 to 1.377]), or compared to the placebo (RR = 1.374; CI [1.153 to 1.638]). In summary, the risk of cardiac or kidney-related events observed in the roxadustat was not significantly increase whether in DD or NDD patients. However, attention must be paid to the occurrence of hyperkalemia for DD patients and hypertension in NDD patients using roxadustat. |
| format | Article |
| id | doaj-art-5dd04732b22b437aab1bafcd0865af08 |
| institution | Kabale University |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-5dd04732b22b437aab1bafcd0865af082025-01-23T04:17:48ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492024-12-0146110.1080/0886022X.2024.2313864Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysisLei Tian0Mengdi Wang1Mengchao Liu2Yanyu Pang3Jingwen Zhao4Bingjie Zheng5Yutong Wang6Wenjing Zhao7Department of Nephrology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, ChinaDepartment of Nephrology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, ChinaDepartment of Nephrology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, ChinaDepartment of Nephrology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, ChinaDepartment of Nephrology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, ChinaDepartment of Nephrology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, ChinaDepartment of Nephrology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, ChinaDepartment of Nephrology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, ChinaThis systematic review and meta-analysis were conducted to evaluate the cardiac and kidney-related adverse effects of roxadustat for the treatment of anemia in CKD patients. 18 trials with a total of 8806 participants were identified for analysis. We employed a fixed-effects model for analysis. The pooled result revealed no significant difference in the risk of occurrence of cardiac disorders when comparing CKD patients receiving roxadustat with the placebo (RR = 1.049; CI [0.918 to 1.200]) or ESA (RR = 1.066; CI [0.919 to 1.235]), in both dialysis-dependent (DD) (RR = 1.094; CI [0.925 to 1.293]) or non-dialysis-dependent (NDD) (RR = 1.036; CI [0.916 to 1.171]) CKD patients. No significant difference was observed in the risk of kidney-related adverse events when comparing roxadustat with the placebo (RR = 1.088; CI [0.980 to 1.209]) or ESA (RR = 0.968; CI [0.831 to 1.152]), in DD (RR = 2.649; CI [0.201 to 34.981]) or NDD (RR = 1.053; CI [0.965 to 1.149]) CKD patients. A high risk of hyperkalemia was observed in the roxadustat group in DD (RR = 0.939; CI [0.898 to 0.981]). Incidence of hypertension was higher in the roxadustat for NDD patients (RR = 1.198; CI [1.042 to 1.377]), or compared to the placebo (RR = 1.374; CI [1.153 to 1.638]). In summary, the risk of cardiac or kidney-related events observed in the roxadustat was not significantly increase whether in DD or NDD patients. However, attention must be paid to the occurrence of hyperkalemia for DD patients and hypertension in NDD patients using roxadustat.https://www.tandfonline.com/doi/10.1080/0886022X.2024.2313864Cardiovascular-related eventskidney-related eventsroxadustatchronic kidney diseaseanemia |
| spellingShingle | Lei Tian Mengdi Wang Mengchao Liu Yanyu Pang Jingwen Zhao Bingjie Zheng Yutong Wang Wenjing Zhao Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis Renal Failure Cardiovascular-related events kidney-related events roxadustat chronic kidney disease anemia |
| title | Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis |
| title_full | Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis |
| title_fullStr | Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis |
| title_full_unstemmed | Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis |
| title_short | Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis |
| title_sort | cardiovascular and renal safety outcomes of hypoxia inducible factor prolyl hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease a systematic review and meta analysis |
| topic | Cardiovascular-related events kidney-related events roxadustat chronic kidney disease anemia |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2313864 |
| work_keys_str_mv | AT leitian cardiovascularandrenalsafetyoutcomesofhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatforanemiapatientswithchronickidneydiseaseasystematicreviewandmetaanalysis AT mengdiwang cardiovascularandrenalsafetyoutcomesofhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatforanemiapatientswithchronickidneydiseaseasystematicreviewandmetaanalysis AT mengchaoliu cardiovascularandrenalsafetyoutcomesofhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatforanemiapatientswithchronickidneydiseaseasystematicreviewandmetaanalysis AT yanyupang cardiovascularandrenalsafetyoutcomesofhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatforanemiapatientswithchronickidneydiseaseasystematicreviewandmetaanalysis AT jingwenzhao cardiovascularandrenalsafetyoutcomesofhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatforanemiapatientswithchronickidneydiseaseasystematicreviewandmetaanalysis AT bingjiezheng cardiovascularandrenalsafetyoutcomesofhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatforanemiapatientswithchronickidneydiseaseasystematicreviewandmetaanalysis AT yutongwang cardiovascularandrenalsafetyoutcomesofhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatforanemiapatientswithchronickidneydiseaseasystematicreviewandmetaanalysis AT wenjingzhao cardiovascularandrenalsafetyoutcomesofhypoxiainduciblefactorprolylhydroxylaseinhibitorroxadustatforanemiapatientswithchronickidneydiseaseasystematicreviewandmetaanalysis |